Predict your next investment

SOFTWARE (NON-INTERNET/MOBILE) | Healthcare Software
softmed.es

See what CB Insights has to offer

Founded Year

1994

Stage

Corporate Minority | Dead

Total Raised

$3.42M

Last Raised

$1.68M

About SoftMed

Provider of software for the healthcare and pharmaceutical industries. The company provides clinical simulation and training software, and produces interactive CD-ROMS on the use of new pharmaceutical products. It also offers health-related audiovisual content for TV broadcast and Web design solutions.

SoftMed Headquarter Location

Centro Empresarial El Plantío C/ Ochandiano, n 6

Madrid, 28023,

Spain

34 91 452 1700

Latest SoftMed News

Melbourne group takes on Ansell in gloves

Feb 28, 2021

Share Melbourne-based manufacturer Softmed pledged to deliver cheaper prices for single-use medical gloves than global $5 billion giant Ansell when it begins making around 2.5 billion gloves annually later this year. General manager Sergiy Tsimidanov said a new plant being established in the Melbourne suburb of Craigieburn will complement its factory at Campbellfield in the city which has produced respirators and 100 million face masks in the past year. Softmed general manager Sergiy Tsimidanov says being able to produce the gloves in Melbourne will be a huge plus. Mr Tsimidanov said countries had realised that local production was crucial in a pandemic for both security of supply and to keep prices down for products that were in huge demand. “We think we can make a better price than Ansell,” he said. The production of single-use gloves for medical examinations and surgical procedures comes after Softmed was able to source enough of a raw material to enable manufacturing to begin from late July. Related Quotes Advertisement “We expect the first batch to be produced in late July or early August,” he said. Softmed has also begun producing surgical and isolation gowns, caps and shoe coverings for the health sector. He said prices of the base chemical for production of the single-use gloves had soared during the pandemic because of heavy demand but the group had secured supplies from Malaysia, Europe and the United States. Enough of the base chemical – nitrile butadiene acrile rubber – had been procured to enable Softmed to hit go on its expansion, which involves a $70 million investment in plant and equipment. Accelerating demand Mr Tsimidanov said there was heavy demand for single-use medical gloves before COVID-19, but there had been a vast acceleration in the past 12 months. He said Softmed would make sure that all of the Australian customers seeking single-use gloves were satisfied before it pursued offshore sales. The group sells face masks around the world. Ansell is a much bigger player in the industry and has a global network of factories in countries including China, Sri Lanka, Malaysia, Vietnam, Thailand, Portugal, Brazil and Lithuania. It has a workforce of 13,500 people. Softmed employs 80 people. Advertisement Ansell chief executive Magnus Nicolin said on February 16 demand would remain high for its products even when the pandemic was under control because of the steady need for better hygiene practices and the potential demand for annual COVID-19 vaccinations to combat a mutating virus. He said the company will bring on eight new production lines in the June half to keep up with the extraordinary demand, after an initial five extra lines were set up in the six months ended December 31. Mr Nicolin said by 2022-23 Ansell would have doubled capacity for production of single-use medical and surgical gloves, and protective suits. A glove plant near Bangkok in Thailand was being heavily expanded, while the group had tripled capacity in Sri Lanka for protective bodysuits, and doubled capacity in China for bodysuits. Ansell’s healthcare division, which makes single-use medical gloves and protective suits used by medical and hospital workers, generated organic growth of 37.3 per cent in the six months ended December 31. The biggest stories in business, markets and politics and why they matter. Need to know. Our daily reporting, in your inbox.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.